Department of Physiology and the Center for Excellence in Cardiovascular-Renal Research, University of Mississippi Medical Center, Jackson, Miss 39216-4505, USA.
Hypertension. 2010 Feb;55(2):380-5. doi: 10.1161/HYPERTENSIONAHA.109.141937. Epub 2009 Dec 21.
Antagonism of vascular endothelial growth factor (VEGF) signaling by soluble fms-like tyrosine kinase 1 occurs during preeclampsia and is proposed to play an important role in the pathogenesis of preeclampsia. We reported recently that hypertension associated with chronic reductions in uteroplacental perfusion pressure (RUPP) is associated with increased soluble fms-like tyrosine kinase 1 and decreased free VEGF. Whether restoration of circulating VEGF can restore renal function and chronically decrease arterial pressure associated with placental ischemia remains unknown. We hypothesized that chronic infusion of VEGF(121) would attenuate hypertension, increase glomerular filtration rate, and reverse the endothelial dysfunction associated with chronic RUPP. VEGF(121) (at either 90 or 180 microg/kg per day) was administered for 5 days via osmotic minipump placed IP. Mean arterial pressure, renal function, and tissues were obtained on day 19 of pregnancy from RUPP+VEGF, RUPP, and normal pregnant dams. Mean arterial pressure was increased in the RUPP (131+/-3 mm Hg) compared with the normal pregnant (102+/-1 mm Hg) rats, and infusion of VEGF(121) resolved the hypertension (105+/-5 mm Hg). Glomerular filtration rate was decreased in the RUPP dams (1.5+/-0.3 mL/min) and restored to normal pregnant levels (3.1+/-0.5 mL/min) by VEGF(121) treatment (3.1+/-0.4 mL/min). Effective renal plasma flow, decreased by RUPP, was also increased by VEGF(121) infusion. Relaxation to acetylcholine was enhanced by the VEGF treatment (P<0.05). These data demonstrate that chronic infusion of VEGF(121) during late gestation restores glomerular filtration rate and endothelial function and reduces high blood pressure associated with placental ischemia. The present results suggest that VEGF(121) may be a candidate molecule for management of preeclampsia and its related complications.
血管内皮生长因子(VEGF)信号的拮抗作用可溶性 fms 样酪氨酸激酶 1 发生在子痫前期,并被认为在子痫前期的发病机制中发挥重要作用。我们最近报道称,与慢性降低胎盘灌注压(RUPP)相关的高血压与可溶性 fms 样酪氨酸激酶 1 增加和游离 VEGF 减少有关。恢复循环 VEGF 是否可以恢复与胎盘缺血相关的肾功能和慢性降低动脉压尚不清楚。我们假设慢性输注 VEGF(121)可以减轻高血压、增加肾小球滤过率,并逆转与慢性 RUPP 相关的内皮功能障碍。通过置于 IP 的渗透微型泵每天给予 VEGF(121)(90 或 180μg/kg)5 天。从 RUPP+VEGF、RUPP 和正常妊娠的母鼠中获得妊娠第 19 天的平均动脉压、肾功能和组织。与正常妊娠(102+/-1mmHg)的大鼠相比,RUPP 中的平均动脉压升高(131+/-3mmHg),并且 VEGF(121)的输注解决了高血压(105+/-5mmHg)。肾小球滤过率在 RUPP 母鼠中降低(1.5+/-0.3ml/min),并通过 VEGF(121)治疗恢复正常妊娠水平(3.1+/-0.5ml/min)(3.1+/-0.4ml/min)。RUPP 降低的有效肾血浆流量也通过 VEGF(121)输注增加。VEGF 处理增强了对乙酰胆碱的松弛作用(P<0.05)。这些数据表明,在妊娠晚期慢性输注 VEGF(121)可恢复肾小球滤过率和内皮功能,并降低与胎盘缺血相关的高血压。目前的结果表明,VEGF(121)可能是治疗子痫前期及其相关并发症的候选分子。